| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C8b |
| Uniprot No | P07358 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 55-591aa |
| 氨基酸序列 | SVDVTLMPIDCELSSWSSWTTCDPCQKKRYRYAYLLQPSQFHGEPCNFSDKEVEDCVTNRPCRSQVRCEGFVCAQTGRCVNRRLLCNGDNDCGDQSDEANCRRIYKKCQHEMDQYWGIGSLASGINLFTNSFEGPVLDHRYYAGGCSPHYILNTRFRKPYNVESYTPQTQGKYEFILKEYESYSDFERNVTEKMASKSGFSFGFKIPGIFELGISSQSDRGKHYIRRTKRFSHTKSVFLHARSDLEVAHYKLKPRSLMLHYEFLQRVKRLPLEYSYGEYRDLFRDFGTHYITEAVLGGIYEYTLVMNKEAMERGDYTLNNVHACAKNDFKIGGAIEEVYVSLGVSVGKCRGILNEIKDRNKRDTMVEDLVVLVRGGASEHITTLAYQELPTADLMQEWGDAVQYNPAIIKVKVEPLYELVTATDFAYSSTVRQNMKQALEEFQKEVSSCHCAPCQGNGVPVLKGSRCDCICPVGSQGLACEVSYRKNTPIDGKWNCWSNWSSCSGRRKTRQRQCNNPPPQNGGSPCSGPASETLDCS |
| 预测分子量 | 67.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于C8b重组蛋白的假设性参考文献示例(仅供格式参考，具体文献需通过学术数据库检索)：
1. **文献名称**: "Recombinant expression and functional characterization of human complement C8β in Escherichia coli"
**作者**: Smith A, et al.
**摘要**: 本研究报道了通过大肠杆菌表达系统高效表达人源C8β重组蛋白，并优化了纯化流程。功能实验表明，重组C8β可与C8αγ亚基组装形成功能性C8复合物，参与补体膜攻击复合物(MAC)的形成。
2. **文献名称**: "Structural insights into C8β role in complement-mediated lysis via cryo-EM"
**作者**: Johnson R, et al.
**摘要**: 通过冷冻电镜技术解析了C8β在MAC中的三维结构，揭示了其与C8α及C9蛋白的相互作用界面，为理解补体系统溶细胞机制提供了结构基础。
3. **文献名称**: "C8β deficiency: Recombinant protein rescue model in zebrafish"
**作者**: Lee H, et al.
**摘要**: 利用斑马鱼模型研究C8β基因缺陷导致的补体功能异常，并通过注射重组人C8β蛋白部分恢复MAC功能，证明其治疗遗传性补体缺陷症的潜在价值。
4. **文献名称**: "High-yield production of glycosylated C8β in mammalian cells for antibody-drug conjugate applications"
**作者**: Chen L, et al.
**摘要**: 开发了哺乳动物细胞表达系统生产糖基化修饰的重组C8β蛋白，并验证其作为靶向药物载体的可行性，为癌症免疫治疗提供新策略。
---
**提示**：以上为模拟示例，实际文献请通过 **PubMed** 或 **Web of Science** 检索关键词(如 "C8b recombinant protein" "complement C8 beta subunit")，并筛选近五年高被引研究。
**Background of Recombinant C8β Protein**
The complement system, a critical component of innate immunity, mediates pathogen clearance via the membrane attack complex (MAC), a pore-forming structure that lyses targeted cells. C8. a key MAC component, is a heterotrimeric protein composed of α-, β-, and γ-subunits. Among these, the C8β subunit plays a pivotal role in MAC assembly by binding to the C5b-7 complex, facilitating membrane insertion and subsequent polymerization of C9 to form functional pores. Dysregulation of MAC activity is linked to diseases like paroxysmal nocturnal hemoglobinuria and age-related macular degeneration, highlighting the need to study its components.
Recombinant C8β (rC8β) protein is produced using genetic engineering, typically by expressing the *C8B* gene in host systems (e.g., *E. coli* or mammalian cells). This approach ensures high purity and scalability, overcoming limitations of isolating native C8β from biological fluids. Advanced techniques like affinity tagging streamline purification, yielding functional protein suitable for structural and mechanistic studies.
Research applications of rC8β include elucidating MAC assembly dynamics, modeling complement-mediated diseases, and screening therapeutic inhibitors. It also serves as a tool for diagnosing complement disorders or evaluating drug efficacy. By enabling precise manipulation of MAC components, recombinant C8β advances our understanding of complement-related pathologies and supports the development of targeted therapies.
In summary, recombinant C8β is indispensable for dissecting MAC biology and bridging translational research in immunology and drug discovery.
(Word count: 249)
×
